Genetic Sequence-Carbohydrate Conjugates for Organ-Specific RNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutics often fail to deliver genetic sequences and active agents safely and efficiently to their target sites in the liver and kidneys, leading to unintended or harmful side effects.
Innovation Solution
Development of genetic sequence-carbohydrate conjugates, particularly peptide nucleic acid (PNA)-carbohydrate conjugates, that selectively target liver and kidney cells by binding to specific receptors, using linkers and functional moieties to enhance delivery and reduce off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutics are delivered to body tissues, then therapeutic effect is achieved, but unintended or harmful side effects occur due to lack of specific targeting
Solution Approach 1:
The patent applies local quality by attaching carbohydrate ligands (such as galactose, N-acetylgalactosamine, or lactobionic acid) to the 5' end of genetic sequences to create organ-specific targeting capabilities. The conjugates are designed to bind selectively to receptors expressed on liver or kidney cell surfaces, enabling localized therapeutic effect in the intended organ while minimizing off-target effects in other tissues.
Solution Approach 2:
The carbohydrate ligand serves as an intermediary molecule that mediates between the therapeutic genetic sequence and the target cell receptor. The ligand binds to specific receptors on the cell surface (such as asialoglycoprotein receptor on liver cells), facilitating selective delivery of the therapeutic agent to the desired tissue while preventing accumulation in non-target organs.
2Productivity
If genetic sequences are delivered to target cells, then therapeutic effect is achieved, but delivery efficiency is insufficient without specific targeting mechanisms
Solution Approach 1:
The patent enhances delivery efficiency by incorporating organ-specific carbohydrate ligands that recognize and bind to receptors uniquely expressed on liver or kidney cell surfaces. This localized recognition mechanism ensures that the genetic sequences are delivered efficiently to the intended target cells rather than distributing randomly throughout the body.
Solution Approach 2:
The carbohydrate ligand acts as a molecular intermediary that facilitates efficient delivery by mediating receptor-mediated endocytosis. The ligand-receptor interaction triggers cellular uptake mechanisms that actively transport the conjugate into the target cell, significantly improving delivery efficiency compared to passive diffusion or non-specific binding methods.
3Quantity of substance
If conventional delivery methods are used, then therapeutic agents reach body tissues, but off-target effects increase due to lack of selectivity
Solution Approach 1:
The patent reduces off-target effects by implementing local quality through organ-specific carbohydrate ligands that are recognized only by receptors present on liver or kidney cells. This specificity ensures that therapeutic agents are delivered quantitatively to the correct organ while preventing accumulation and harmful effects in other body tissues.
Solution Approach 2:
The carbohydrate ligand serves as a selective intermediary that mediates the interaction between the therapeutic agent and target cells. The ligand-receptor binding specificity acts as a molecular filter, allowing therapeutic delivery to proceed only when the correct target organ is encountered, thereby eliminating off-target effects while maintaining adequate therapeutic quantity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates effectively deliver therapeutic agents to liver and kidney cells, reducing expression of targeted RNAs and modulating gene expression, thereby treating conditions such as liver and kidney diseases, including renal fibrosis and cancer, with minimal side effects.
Implementation Method 1
The conjugate selectively binds to specific receptors on cells to deliver the genetic sequence or other therapeutic agent to the cells bearing the receptors
Data Source
AI summary
A genetic sequence-carbohydrate conjugate is disclosed, having a formula (I): wherein GS is a genetic sequence, preferably a peptide nucleic acid or an oligonucleotide such as an mRNA sequence, an siRNA Sequence, or a DNA sequence, optionally wherein each genetic sequence is natural or modified, and the variables are as described herein. Also disclosed are uses for the genetic sequence-carbohydrate conjugates, including as RNA therapeutics targeting the liver and kidneys of a mammal, including a human.